Document is current
Any future updates will be listed below
-
Authors
Andersson, Emelie
Lindblom, Nils https://orcid.org/0009-0000-6641-9777
Janelidze, Shorena https://orcid.org/0000-0003-2869-8378
Salvadó, Gemma https://orcid.org/0000-0002-5210-9230
Gkanatsiou, Eleni
Söderberg, Linda
Möller, Christer
Lannfelt, Lars
Ge, Junyue
Hanrieder, Jörg
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Deierborg, Tomas
Mattsson-Carlgren, Niklas
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Gouras, Gunnar https://orcid.org/0000-0002-5500-6325
Hansson, Oskar https://orcid.org/0000-0001-8467-7286
- License Information
-
More Information
Article History
Received: 19 June 2023
Accepted: 9 January 2025
First Online: 12 February 2025
Competing interests
: O.H. has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare and Roche. In the past 2 years, he has received consultancy and speaker fees from ALZpath, BioArctic, Biogen, Bristol Meyer Squibb, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. H.Z. has served on scientific advisory boards or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen Pharma, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena Biosciences, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, AlzeCure Pharma, Biogen and Roche, and is a cofounder of Brain Biomarker Solutions in Gothenburg, which is a part of the GU Ventures Incubator Program (outside the submitted work). K.B. has served as a consultant, on advisory boards or data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu, Julius Clinical, Eli Lilly, MagQu, Novartis, Ono Pharmaceutical, PharmatrophiX, Prothena, Roche Diagnostics and Siemens Healthineers, and is a cofounder of Brain Biomarker Solutions in Gothenburg, outside the work presented in this paper. The other authors declare no competing interests.
